AbbVie Inc. (ABBV) Interest Expense
The interest expense for AbbVie Inc. (ABBV) is $2.89 Billion with a year-over-year change of +3.03%. Interest expense is the cost a company incurs for borrowed funds, including interest on bonds, loans, and other forms of debt financing.
ABBV Interest Expense Chart
Current Interest Expense
$2.89B
$2.89 Billion
Year-over-Year Change
+3.03%
vs. $2.81B prior year
Historical Data
17
Years of data available
Annual Interest Expense History
| Year | Interest Expense | YoY Change | % Change |
|---|---|---|---|
| 2025 | $2.89B | +$85.00M | +3.03% |
| 2024 | $2.81B | +$584.00M | +26.26% |
| 2023 | $2.22B | $-6.00M | -0.27% |
| 2022 | $2.23B | $-193.00M | -7.97% |
| 2021 | $2.42B | $-31.00M | -1.26% |
| 2020 | $2.45B | +$670.00M | +37.56% |
| 2019 | $1.78B | +$436.00M | +32.34% |
| 2018 | $1.35B | +$198.00M | +17.22% |
| 2017 | $1.15B | +$103.00M | +9.84% |
| 2016 | $1.05B | +$328.00M | +45.62% |
| 2015 | $719.00M | +$290.00M | +67.60% |
| 2014 | $429.00M | +$130.00M | +43.48% |
| 2013 | $299.00M | +$195.00M | +187.50% |
| 2012 | $104.00M | +$104.00M | — |
| 2011 | $0 | +$0 | — |
| 2010 | $0 | +$0 | — |
| 2009 | $0 | — | — |
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael